Pennsylvania is currently home to 3310 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Research Site, Pittsburgh, Pennsylvania
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
NCT05184088
Recruiting
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
Register for Updates
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862
Recruiting
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Mainline Health Lankenau Institute For Medical Research, Wynnewood, Pennsylvania
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Register for Updates
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
NCT04549116
Recruiting
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical study in women aged 35 to 42 years. This study will investigate the safety and efficacy of Progesterone-IBSA to support euploid embryo blastocyst implantation and early pregnancy after frozen embryo transfer (FET) in a modified natural cycle as a treatment for infertile women. Subjects will be randomized to receive either active Progesterone-IBSA or Crinone 8% for luteal and early pregnancy... Read More
Gender:
FEMALE
Ages:
Between 35 years and 42 years
Trial Updated:
06/23/2025
Locations: Main Line Fertility, Bryn Mawr, Pennsylvania
Conditions: Infertility
Register for Updates
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
NCT04482933
Recruiting
This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric high-grade gliomas
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
06/23/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
Register for Updates
CapTemY90 for Grade 2 NET Liver Metastases
NCT04339036
Recruiting
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
Register for Updates
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/23/2025
Locations: Corporal Michael J. Crescenz VA Medical Center-Philadelphia VA, Philadelphia, Pennsylvania
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935
Recruiting
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Gender:
ALL
Ages:
All
Trial Updated:
06/23/2025
Locations: Paoli Memorial Hospital, Paoli, Pennsylvania
Conditions: Malignant Neoplasm
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Jefferson Abington Hospital, Abington, Pennsylvania
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018
Recruiting
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/23/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Register for Updates
A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia
NCT06651515
Recruiting
This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose. Although this study is open to patients with all HLA or blood types, immunosuppression to prevent rejection will be required in this first in human study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/22/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Diabetes Mellitus Type 1
Register for Updates
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
NCT06884865
Recruiting
The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is. Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse e... Read More
Gender:
ALL
Ages:
Between 45 years and 80 years
Trial Updated:
06/21/2025
Locations: Altoona Center for Clinical Research, Duncansville, Pennsylvania
Conditions: Osteoarthritis (OA) of the Knee
Register for Updates